SCHEMBL16257539

SCHEMBL16257539

COc1ccc(/C=C/C(=O)c2cccc(N)c2)cc1OC

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.74
CA1 P00915 1/20 0.74
CA2 P00918 1/20 0.74
ABCG2 Q9UNQ0 3/20 0.72
MEN1 O00255 1/20 0.70
KMT2A Q03164 1/20 0.70
ABCB1 P08183 2/20 0.69
RELA Q04206 1/20 0.67
PDE4A P27815 1/20 0.64
PDE4B Q07343 1/20 0.64
PDE4C Q08493 1/20 0.64
PDE4D Q08499 1/20 0.64
CYP1A1 P04798 2/20 0.64
CYP1A2 P05177 2/20 0.64
CYP2D6 P10635 2/20 0.64
CYP1B1 Q16678 2/20 0.64
CYP3A4 P08684 1/20 0.64
TNFRSF1A P19438 2/20 0.64
PTGS2 P35354 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29803052 1.00 NR1H4 (0.74) NR1H4CA1CA2ABCG2MEN1
SCHEMBL2221923 0.90 RELA (0.68) NR1H4CA1CA2RELAPTGS2
SCHEMBL2221920 0.90 RELA (0.68) NR1H4CA1CA2RELAPTGS2
SCHEMBL14760795 0.87 ABCB1 (0.82) CA1CA2ABCG2MEN1KMT2A
SCHEMBL14760794 0.87 ABCB1 (0.82) CA1CA2ABCG2MEN1KMT2A
SCHEMBL16257540 0.87 ABCB1 (0.65) NR1H4CA1CA2ABCG2ABCB1
SCHEMBL20106717 0.85 NR1H4 (0.76) NR1H4CA1CA2ABCG2MEN1
SCHEMBL29803121 0.85 NR1H4 (1.00) NR1H4ABCG2MEN1KMT2AABCB1
SCHEMBL611778 0.85 NR1H4 (1.00) NR1H4ABCG2MEN1KMT2AABCB1
SCHEMBL499242 0.85 NR1H4 (1.00) NR1H4ABCG2MEN1KMT2AABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540144-B2 Rapafucin derivative compounds and methods of use thereof THE JOHNS HOPKINS UNIVERSITY (US) 2026-02-03 US disclosed
US-20240239810-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2024-07-18 US disclosed
US-11945827-B2 Rapafucin derivative compounds and methods of use thereof THE JOHNS HOPKINS UNIVERSITY (US) 2024-04-02 US disclosed
US-20230000996-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2023-01-05 US disclosed
US-20230000996-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2023-01-05 US disclosed
US-20220363692-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2022-11-17 US disclosed
EP-4037702-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF The Johns Hopkins University (US) 2022-08-10 EP disclosed
CN-114746103-A Rapafucin derivative compounds and methods of use thereof 约翰霍普金斯大学 2022-07-12 CN disclosed
US-11066416-B2 Rapafucin derivative compounds and methods of use thereof THE JOHNS HOPKINS UNIVERSITY (US) 2021-07-20 US disclosed
US-11066416-B2 Rapafucin derivative compounds and methods of use thereof THE JOHNS HOPKINS UNIVERSITY (US) 2021-07-20 US disclosed
WO-2021067405-A1 NEUROPROTECTIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY (US) 2021-04-08 WO disclosed
US-20210094933-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2021-04-01 US disclosed
US-20210094933-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2021-04-01 US disclosed
US-10774110-B2 Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof THE JOHNS HOPKINS UNIVERSITY (US) 2020-09-15 US disclosed
US-20200040004-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RAPAFUSYN PHARMACEUTICALS, INC. 2020-02-06 US disclosed
US-20200040004-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RAPAFUSYN PHARMACEUTICALS, INC. 2020-02-06 US disclosed
US-20190092808-A1 SYNTHESIS AND COMPOSITION OF RAPAFUCIN LIBRARIES THE JOHNS HOPKINS UNIVERSITY 2019-03-28 US disclosed
US-20190031716-A1 RAPADOCINS, INHIBITORS OF EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1 AND USES THEREOF THE JOHNS HOPKINS UNIVERSITY 2019-01-31 US disclosed
WO-2017136708-A1 SYNTHESIS AND COMPOSITION OF RAPAFUCIN LIBRARIES THE JOHNS HOPKINS UNIVERSITY (US) 2017-08-10 WO disclosed
US-8889874-B2 Imidazolone-chalcone derivatives as potential anticancer agent and process for the preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2014-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066416-B2 Rapafucin derivative compounds and methods of use thereof RICTOR, FKBP14, MTOR NR1H4 1419/4885CA1 4842/4885CA2 4766/4885
US-20190031716-A1 RAPADOCINS, INHIBITORS OF EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1 AND USES THEREOF SLC29A1, SLC29A2, SLC2A1 NR1H4 575/4885CA1 4268/4885CA2 2773/4885
US-20220363692-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR NR1H4 1419/4885CA1 4842/4885CA2 4766/4885
US-20200040004-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR NR1H4 1419/4885CA1 4842/4885CA2 4766/4885
US-20230000996-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR NR1H4 1419/4885CA1 4842/4885CA2 4766/4885
US-20210094933-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR NR1H4 1419/4885CA1 4842/4885CA2 4766/4885
US-10774110-B2 Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof SLC29A1, SLC29A2, SLC2A1 NR1H4 575/4885CA1 4268/4885CA2 2773/4885
US-20190092808-A1 SYNTHESIS AND COMPOSITION OF RAPAFUCIN LIBRARIES MTOR, COASY, RICTOR NR1H4 2643/4885CA1 4716/4885CA2 4782/4885
US-11945827-B2 Rapafucin derivative compounds and methods of use thereof RICTOR, FKBP14, MTOR NR1H4 1419/4885CA1 4842/4885CA2 4766/4885
US-12540144-B2 Rapafucin derivative compounds and methods of use thereof RICTOR, CHP1, FKBP8 NR1H4 275/4885CA1 4237/4885CA2 2519/4885
US-20240239810-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, MTOR, FKBP14 NR1H4 1936/4885CA1 4844/4885CA2 4750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.